Developments in pharmacotherapy for tobacco dependence: past, present and future
UMass Chan Affiliations
Department of PsychiatryDocument Type
Journal ArticlePublication Date
2006-02-24Keywords
AdolescentAdult
Bupropion
Clinical Trials as Topic
Clonidine
Drug Administration Routes
Female
Humans
Male
Nicotine
Nicotinic Agonists
Nortriptyline
Pregnancy
Smoking
Smoking Cessation
Treatment Outcome
Psychiatry
Metadata
Show full item recordAbstract
In the mid-1970s there were no effective pharmacological treatments for tobacco dependence. The invention of nicotine gum was a major treatment advance and also greatly helped our understanding of the nature of tobacco dependence. There are now eight effective pharmacotherapies (nicotine gum, patch, nasal spray, inhaler, lozenge/tablet, bupropion, nortriptyline and clonidine) available to aid smoking cessation. Other non-nicotine agents that show promise are under investigation, including glucose, rimonabant, selegiline and varenicline. Greater knowledge of the mechanisms of action of the effective non-nicotine agents should lead to better understanding of the nature of tobacco dependence. Future research into optimal treatments should examine long-term combination pharmacotherapy combined with improved psychosocial support that is partly designed to enhance medication compliance. In addition, there is a need for studies designed to evaluate the efficacy of pharmacotherapies in populations such as youth, pregnant smokers and smokers with co-occurring mental health problems.Source
Drug Alcohol Rev. 2006 Jan;25(1):59-71. Link to article on publisher's siteDOI
10.1080/09595230500459529Permanent Link to this Item
http://hdl.handle.net/20.500.14038/45675PubMed ID
16492578Related Resources
Link to Article in PubMedae974a485f413a2113503eed53cd6c53
10.1080/09595230500459529